Clene Confident In Phase III Plans For CNM-Au8 In ALS With Six-Month Data

 
• By Alaric DeArment

The company announced detailed data for the drug in the HEALEY-ALS Platform Trial, where the cohort of the Phase II/III study testing it nevertheless failed to meet the primary endpoint.

Clene announced data on CMN-Au8 from the HEALEY ALS Platform Trial • Source: Shutterstock

More from Strategy

More from Business